- Home
- Publications
- Publication Search
- Publication Details
Title
The Ascension of Targeted Covalent Inhibitors
Authors
Keywords
-
Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 8, Pages 5886-5901
Publisher
American Chemical Society (ACS)
Online
2022-04-20
DOI
10.1021/acs.jmedchem.1c02134
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2021 FDA approvals
- (2022) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- BTK blockers make headway in multiple sclerosis
- (2021) Elie Dolgin NATURE BIOTECHNOLOGY
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
- (2021) Gregory J. Riely et al. Cancer Discovery
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
- (2021) H. Yesid Estupiñán et al. Frontiers in Cell and Developmental Biology
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- (2021) Brett King et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
- (2021) Ying C. Ou et al. LEUKEMIA & LYMPHOMA
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
- (2021) Marwan G Fakih et al. LANCET ONCOLOGY
- Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and β-Lactams
- (2021) Søren Brøgger Christensen MOLECULES
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
- (2020) Clare CHUI LING Sun et al. BLOOD
- Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
- (2020) Yuqin Song et al. CLINICAL CANCER RESEARCH
- A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY
- (2020) Constantine S. Tam et al. BLOOD
- Covalent inhibitors: back on track?
- (2020) Matthias Gehringer Future Medicinal Chemistry
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
- (2020) Karthick Vishwanathan et al. Pharmacology Research & Perspectives
- 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
- (2020) S.S. Schalm et al. ANNALS OF ONCOLOGY
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization
- (2020) Atli Thorarensen et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come
- (2019) Craig Furman et al. CANCER RESEARCH
- Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity
- (2019) Marie‐Noëlle Paludetto et al. MEDICINAL RESEARCH REVIEWS
- Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
- (2019) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
- (2019) Collins et al. Cancers
- Target 2035: probing the human proteome
- (2019) Adrian J. Carter et al. DRUG DISCOVERY TODAY
- Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy
- (2019) Carlo Baggio et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
- (2019) Brian A. Lanman et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Structurally-Validated Multiple Sequence Alignment of 497 Human Protein Kinase Domains
- (2019) Vivek Modi et al. Scientific Reports
- The Taxonomy of Covalent Inhibitors
- (2018) Alfred Tuley et al. BIOCHEMISTRY
- High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies
- (2018) Peter Dreger et al. BLOOD
- Structure-based design of targeted covalent inhibitors
- (2018) Richard Lonsdale et al. CHEMICAL SOCIETY REVIEWS
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis
- (2018) Jennifer R. Brown et al. BRITISH JOURNAL OF HAEMATOLOGY
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
- (2018) Funda Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- The first 3500 years of aspirin history from its roots – A concise summary
- (2018) Maria Rosa Montinari et al. VASCULAR PHARMACOLOGY
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Global profiling of lysine reactivity and ligandability in the human proteome
- (2017) Stephan M. Hacker et al. Nature Chemistry
- Proteasome inhibitors in cancer therapy
- (2017) Elisabet E. Manasanch et al. Nature Reviews Clinical Oncology
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- Targeted Covalent Inhibitors for Drug Design
- (2016) Thomas A. Baillie ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
- (2016) Sven Wind et al. CLINICAL PHARMACOKINETICS
- 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph
- (2016) Nicholas A. Meanwell JOURNAL OF MEDICINAL CHEMISTRY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-l-lysine as an amine nucleophile
- (2016) Upendra P. Dahal et al. MedChemComm
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
- (2014) V. Hirsh et al. Current Oncology
- Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors
- (2014) Mark E. Flanagan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
- (2014) Barbara Melosky et al. Frontiers in Oncology
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
- (2013) Mariana Nacht et al. JOURNAL OF MEDICINAL CHEMISTRY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
- (2012) Iana M Serafimova et al. Nature Chemical Biology
- LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery
- (2011) Roman A. Laskowski et al. Journal of Chemical Information and Modeling
- Managing the challenge of chemically reactive metabolites in drug development
- (2011) B. Kevin Park et al. NATURE REVIEWS DRUG DISCOVERY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine
- (2010) Margit Hagel et al. Nature Chemical Biology
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
- (2009) K.-K. Wong et al. CLINICAL CANCER RESEARCH
- Electrophilic Affibodies Forming Covalent Bonds to Protein Targets
- (2009) Lotta Holm et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Covalent Modifiers: An Orthogonal Approach to Drug Design
- (2009) Michele H. Potashman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
- (2008) Allan Wissner et al. ARCHIV DER PHARMAZIE
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More